Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Eur J Surg Oncol. 2023 Nov;49(11):106980. doi: 10.1016/j.ejso.2023.07.006. Epub 2023 Jul 6.
Low skeletal muscle mass index (SMI) is frequently identified in gastric cancer patients but its association with patient survival rate is not clear. This systematic review and meta-analysis aimed to clarify the association between SMI and overall survival in gastric cancer patients after gastrectomy.
PubMed, Scopus, and Web of Science were searched from database inception until July 2021. Studies were eligible if they included gastric cancer patients, measured the SMI level, reported SMI before gastrectomy, defined sarcopenia according to SMI, and had a cohort or case-control design. Primary outcome was cancer survival rate. The risk of bias of individual studies was assessed using the Newcastle - Ottawa Scale.
Overall, 22 cohort studies including 7,203 participants were included. The quality of the included studies was moderate to high. A higher overall survival rate was associated with a higher SMI (RR = 1.62, 95% CI: 1.42-1.85). Subgroup analysis suggested a stronger association in overweight or obese patients (RR = 2.39, 95% CI: 1.13-5.09; I = 77%; heterogeneity P < 0.01). But no significant differences in the association based on the surgery type (curative surgery vs radical surgery) or the type of gastrectomy (total gastrectomy vs sub-total gastrectomy) were observed.
It is suggested that SMI can be a prognostic indicator for overall survival in gastric cancer patients, especially in overweight and obese patients.
低骨骼肌指数(SMI)在胃癌患者中经常被发现,但它与患者生存率的关系尚不清楚。本系统评价和荟萃分析旨在阐明胃癌患者胃切除术后 SMI 与总体生存率之间的关系。
从数据库建立到 2021 年 7 月,检索了 PubMed、Scopus 和 Web of Science。如果研究包括胃癌患者、测量了 SMI 水平、报告了胃切除术前的 SMI、根据 SMI 定义了肌肉减少症,并且采用了队列或病例对照设计,则符合入选标准。主要结局是癌症生存率。使用纽卡斯尔-渥太华量表评估个体研究的偏倚风险。
共有 22 项队列研究纳入了 7203 名参与者。纳入研究的质量为中等到高度。较高的总体生存率与较高的 SMI 相关(RR=1.62,95%CI:1.42-1.85)。亚组分析表明,超重或肥胖患者的相关性更强(RR=2.39,95%CI:1.13-5.09;I=77%;异质性 P<0.01)。但基于手术类型(根治性手术与根治性手术)或胃切除术类型(全胃切除术与次全胃切除术),这种相关性没有显著差异。
SMI 可作为胃癌患者总体生存率的预后指标,尤其是在超重和肥胖患者中。